anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patient blood group (BG) is predictive for von-Willebrand-factor (VWF) and Factor VIII variation. The clinical impact of this ABO-effect on blood loss, cardiovascular complications and outcome has been described for several patient cohorts. The aim of this study was to investigate the impact of patient BG on blood loss and outcome after coronary artery bypass surgery (CABG). Patient records, intraoperative data and perioperative transfusion records of 5713 patients receiving an on-pump CABG procedure between 05/2004 and 12/2018 were analyzed. A logistic regression model for death due to perioperative myocardial ischaemia (PMI) was developed from initially 24 variables by using an univariate and multivariate selection process. BG AB patients required less blood transfusions as compared to the other blood groups, especially in case of emergency operations. However, BG AB patients also had a higher mortality which was due to secondary cardiovascular complications. The impact of blood type on the rate of cardiovascular mortality was confirmed in the logistic regression model. BG AB patients have a worse outcome after CABG surgery due to an increased incidence of fatal cardiovascular complications. As perioperative myocardial ischemia due to graft occlusion appears to be the most likely explanation, stricter anticoagulation for BG AB patients should be discussed.
A method of manufacturing a cannabinoid solution. The method first comprises providing a solution containing a volume of cannabidiol (CBD), as an oil. Preferably, the solution comprises at least 80% by volume of the CBD oil. The method also includes placing the volume of CBD oil into a container. The method further comprises determining a vibrational frequency of energy. The method then includes applying the determined vibrational frequency of energy to the solution within the container in order to imprint the volume of cannabinoid solution with the determined vibrational frequency. A cannabinoid solution comprising a volume of cannabidiol (CBD), as an oil, is also provided. The solution has been imprinted with one or more selected vibrational frequencies of energy.
Antiphospholipid Antibody Syndrome (APL) is an autoimmune disease that increases ones risk for blood clots. Therefore, these patients receive anticoagulation therapy with warfarin. Point of care devices such as the CoaguChek XS are often used to monitor International Normalized Ratio (INR) in patients on warfarin. However, the antibodies present in patients with APL may lead to false INR results when using the CoaguChek XS. This study will compare the accuracy of the CoaguChek XS in measuring INR in patients with APL by measuring INR by the CoaguChek XS and a standard lab as a reference point. Patients on warfarin for indications other than APL will be measured by both methods as well to serve as a control group.
Methods of treating certain types of cancer with ganetespib are disclosed. Also provided are methods of treating certain types of cancer with ganetespib in combination with a taxane derivative, and a platinum-containing anticancer agent. Also provided are methods of treating certain types of cancer with p53 mutation by a combination of ganetespib with a taxane derivative, and a platinum-containing anticancer agent. Also provided are methods of treating certain types of cancer with ganetespib in combination with a platinum-containing anticancer agent, and an antimetabolite. Also provided are methods of treating certain types of cancer with ganetespib in combination with a taxane derivative, an anthracycline derivative, and an alkylating antineoplastic agent. Also provided is a pharmaceutical composition comprising ganetespib and one or more other anticancer agents as described above.
An interferon vaginal effervesce tablet containing interferon and adjuvant is provided.Said interferon prefers recombined human interferon alpha 2b. Said adjuvant of said interferon vaginal effervesce tablet contains effervesce agent, bulking agent, disintegrating agent and binder. Said effervesce agent prefers tartaric acid, boric acid and sodium bicarbonate. Said bulking agent prefers starch. Said disintegrating agent prefers carboxymethyl starch. Said binder prefers polyvinylpyrrolidone(PVP) K-30. A method for preparing interferon vaginal effervesce tablet is also provided.
Deaths, cardiac and respiratory, have been reported during initiation and conversion of pain patients to methadone treatment from treatment with other opioid agonists. It is critical to understand the pharmacokinetics of methadone when converting patients from other opioids (see DOSAGE AND ADMINISTRATION). Particular vigilance is necessary during treatment initiation, during conversion from one opioid to another, and during dose titration.

Respiratory depression is the chief hazard associated with methadone hydrochloride administration. Methadone's peak respiratory depressant effects typically occur later, and persist longer than its peak analgesic effects, particularly in the early dosing period. These characteristics can contribute to cases of iatrogenic overdose, particularly during treatment initiation and dose titration.

In addition, cases of QT interval prolongation and serious arrhythmia (torsades de pointes) have been observed during treatment with methadone. Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction.

Methadone treatment for analgesic therapy in patients with acute or chronic pain should only be initiated if the potential analgesic or palliative care benefit of treatment with methadone is considered and outweighs the risks.
The invention discloses controlled release suspension of ambroxol hydrochloride which is controlled to release in a gastrointestinal tract environment. The preparation contains the ambroxol hydrochloride and pharmaceutically acceptable polymer. The suspension comprises the following components in percentage by weight: 10 to 90 percent of ambroxol hydrochloride and 10 to 90 percent of auxiliary material. The auxiliary material having the controlled-release effect is of one or more of cation exchange resin, methylcellulose, ethylcellulose, acrylic resin and Hydroxypropylmethyl Cellulose. Compared with the rapid-release preparation, the suspension can maintain the valid blood concentration within 24 hours, can improve the treatment effect, has small toxic and side effect, is convenient to take and carry, and can reduce the taking times. Compared with the slow-release preparation, the suspension can maintain more stable blood concentration within 24 hours, can improve the treatment effect, and has small toxic and side effect. The suspension is only required to be taken one time every day. The suspension is used as phlegm medicine clinically.
The median age of patients in all studies of first-line and second-line treatment of metastatic breast cancer was 64-65 years. About 1/3 of the patients were greater than or equal to 70 years old. In the first-line study, patients greater than or equal to 70 years of age experienced longer time to tumor progression and higher response rates than patients less than 70.   
  
For the extended adjuvant setting (MA-17), more than 5,100 postmenopausal women were enrolled in the clinical study. In total, 41% of patients were aged 65 years or older at enrollment, while 12% were 75 or older. In the extended adjuvant setting, no overall differences in safety or efficacy were observed between these older patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.   
  
In the adjuvant setting (BIG 1-98), more than 8,000 postmenopausal women were enrolled in the clinical study. In total, 36 % of patients were aged 65 years or older at enrollment, while 12% were 75 or older. More adverse reactions were generally reported in elderly patients irrespective of study treatment allocation. However, in comparison to tamoxifen, no overall differences with regards to the safety and efficacy profiles were observed between elderly patients and younger patients.
Background: The biologics derived from human amniotic membranes (AMs) demonstrate potential pain-inhibitory effects in clinical settings. However, the molecular basis underlying this therapeutic effect remains elusive. HC-HA/PTX3 is a unique water-soluble regenerative matrix that is purified from human AMs. We examined whether HC-HA/PTX3 can modulate the gene networks and transcriptional signatures in the dorsal root ganglia (DRG) neurons transmitting peripheral sensory inputs to the spinal cord. Methods: We conducted bulk RNA-sequencing (RNA-seq) of mouse DRG neurons after treating them with HC-HA/PTX3 (15 µg/mL) for 10 min and 24 h in culture. Differential gene expression analysis was performed using the limma package, and Gene Ontology (GO) and protein-protein interaction (PPI) analyses were conducted to identify the networks of pain-related genes. Western blotting and in vitro calcium imaging were used to examine the protein levels and signaling of pro-opiomelanocortin (POMC) in DRG neurons. Results: Compared to the vehicle-treated group, 24 h treatment with HC-HA/PTX3 induced 2047 differentially expressed genes (DEGs), which were centered on the ATPase activity, receptor-ligand activity, and extracellular matrix pathways. Importantly, PPI analysis revealed that over 50 of these DEGs are closely related to pain and analgesia. Notably, HC-HA/PTX3 increased the expression and signaling pathway of POMC, which may affect opioid analgesia. Conclusions: HC-HA/PTX3 induced profound changes in the gene expression in DRG neurons, centered around various neurochemical mechanisms associated with pain modulation. Our findings suggest that HC-HA/PTX3 may be an important biological active component in human AMs that partly underlies its pain inhibitory effect, presenting a new strategy for pain treatment.
We will randomize providers to three groups. Patients whose provider has been randomized to usual care will not receive IVR calls but do have available a guideline-level weight management service in TCL. Groups one and two will receive pre-visit and post-referral calls. The pre-visit call will invite patients who want to discuss weight at their upcoming visit with their provider to remember to do so. The post-referral call will remind patients that they have received a referral and encourage them to schedule a visit with the community based weight intervention program. Patients whose provider has been randomized to group 1 will receive IVR calls using their scheduled and referring provider's voice. Group 2 will receive IVR calls using a standard IVR voice.
The control group performed active mobilization of members, circumduction of cervical, scapular girdle and extremities, breathing exercises with no loads, set on three to five repetitions only and no stretch exercises. The exercises were performed during the hemodialysis session, three times per week and did not exceed 5 minutes.
The present invention relates generally to a novel protein, Blo t 3, and to derivatives, homologs, analogs, chemical equivalents and mimetics thereof capable of inducing, upregulating or otherwise facilitating the induction of an immune response to a mite and, more particularly, the Blomia tropicalis mite from the family Glycyphagidae. These mites include dust mites and storage mites. The present invention also contemplates a genetic sequence encoding such a protein molecule or its derivatives or homologs. The genetic sequence may be used to generate recombinant allergens or in genetic immunization protocols. Genetic immunization is also a convenient means of generating antibodies to the allergens. The present invention provides, therefore, a genetic vaccine and other compositions comprising a nucleic acid molecule described herein. In one particular embodiment, the novel protein molecule and genetic sequence of the present invention relate to a polymorphic variant of known mite allergen Blo t 12. Such a polymorphic variant alone or in combination with known allergens provide the possibility for developing more comprehensive tests for potential allergic responses. The protein and genetic molecules of the present invention are useful, inter alia, in a range of therapeutic, prophylactic and diagnostic applications.
Objective: To evaluate the association between physical exercise for obese or overweight women and the maternal, perinatal outcomes and perception of these women about their quality of life.

Methods: A randomized controlled clinical trial with 78 pregnant women. Overweight or obese (BMI ≥ 26 kg / m²), gestational age between 14 and 24 weeks and from age 18 years were included. They will be divided into two random groups: one which will an exercise program under supervision and guidance received from home exercises (study group) and another that followed the standard routine prenatal care service (control group). Both groups will receive standardized nutritional counseling by the department of nutrition and dietetics and a questionnaire measuring quality of life WHOQOL-short at 14 - 24 weeks and at 36 weeks of pregnancy. The intervention results will be analyzed by intention to treat. A P value less than 0.05 will be used to determine statistical significance.
For many people, mechanical low back pain (LBP) is a long-term, function-limiting condition rather than a short-term, self-limiting condition. Exercise is one of the primary non-surgical approaches used worldwide for managing LBP. Specifically in people with chronic LBP, exercise has been found to be as efficacious, if not more efficacious than 1) no treatment, 2) usual care, and 3) many other treatments, such as massage or laser therapy. Despite the growing body of evidence for the beneficial effects of exercise, however, there is limited evidence about 1) which exercise is best for which person, 2) how long the effects of different exercises last, 3) which types of exercise people will adhere to, and for how long, and 4) the mechanisms underlying the effects of different types of exercise.

This study aims to address these limitations by directly comparing the effects of 1) exercise to increase strength of the trunk and increase flexibility of the trunk and extremities, and 2) individualized, motor skill training directed at performance of daily functional activities that are painful or limited due to the person's LBP. This study also will examine 1) the effects of a booster phase of intervention, 2) the relationship between adherence to intervention and function, and 3) the relationship between performance of functional activities and function-related outcomes. People with chronic LBP will be randomized to 1) an intervention of strength and flexibility exercise or motor skill training, and 2) a booster or no-booster intervention. Intervention will be provided in 2 phases: 1) initial phase: 6 - 1 hour sessions, once/week for 6 weeks, and 2) booster phase: # of sessions needed to regain independence in home program, beginning 6 months after the initial phase. The investigators will collect 1) measurements of pain, function, disability, and economic outcomes, 2) reports of adherence, and 3) laboratory-based measures of performance of functional activities. People will be followed for 12 months after the initial intervention phase. Three sets of hypotheses are proposed. First, the investigators hypothesize that both interventions will result in improvements in pain, function, disability, and economic outcomes, but that the motor skill training will result in more long lasting improvements than the strength and flexibility exercise. Second, the investigators hypothesize that the effect of a booster phase of intervention will 1) result in longer lasting improvement in function and better adherence than a no-booster intervention, and 2) be greater for motor skill training than for strength and flexibility exercise. Finally, the investigators hypothesize that 1) adherence to motor skill training will be more strongly related to function than will adherence to strength and flexibility exercise, and 2) performance of functional activities by people receiving motor skill training will be more strongly related to function than performance of functional activities by people receiving strength and flexibility exercise.
NEW MATERIAL:A compound expressed by the formula (M is cation). EXAMPLE:Halenaquinol.sulfate. USE:A reverse transcriptase inhibitor. PREPARATION:Methanol is added to Xestospongia sepra collected in KUCHINORABU NISHIURA in KAGOSHIMA Prefecture and the resultant mixture is allowed to stand at 4 deg.C for 24hr. The obtained mixture is then filtered through absorbent cotton to provide a filtrate. Water is subsequently added thereto and the prepared solution is passed through an ion exchange resin column equilibrated with 25% methanol to adsorb an active substance thereon. The aforementioned column is then washed with 25% methanol and the active substance is subsequently eluted with 100% methanol. The resultant eluate is then concentrated and evaporated to dryness. Water is subsequently added thereto to dissolve the obtained solid substance. Ethyl acetate is added to separate and partition the liquid mixture into layers. The obtained aqueous layer is concentrated and evaporated to dryness and the formed solid substance is dissolved in methanol and subjected to gel filtration.
The present invention relates to decoction for curing heart diseases. Cherokee rose fruit is obtained by a weight ratio and is cleaned and aired. 200g of honey is obtained by weighing. The cherokee rose fruit is boiled for 30 minutes by the water of two times. Then, juice is filtrated and honey is added, is uniformly stirred and then is cooled for being drunk as tea. The present invention has the advantages of simple admit, high safety, non toxic side effects, long-term admit, obvious increase of appetite, single medication and obvious effect, prevents the recurrence of heart diseases and fundamentally cures the heart diseases. By clinical application certification, cured patients with the heart diseases have little recurrence.
effect of post covid-19 on dynamic balance in patients after recovery from COVID disease.

patients will treated with medical protocol of COVID 19 an out-patient clinic , and followed up by the chest specialist . The balance tests of the patients were performed 2 to 14 weeks after their recovery from the disease, which was confirmed by the evaluations of the COVID staff and negative polymerase chain reaction test.the patients will evaluated using questionnaires. First, the question will whether feeling in balance in the daily life or not. The answer will classified as "yes"or "no". Second, asked to fill "Dizziness Handicap Inventory"(DHI), which is a multidimensional self- assessment scale created to evaluate the effects of dizziness and balance problems on the quality of life as well as the level of disability of the patients. Assess balance , which consists of a movable balance platform that provides up to 20 of surface tilt in a 360 range of motion. The platform is interfaced with computer software that enables the device to serve as an objective assessment of balance . The measure of postural stability includes the overall (OA), the anteroposterior (AP) and the mediolateral (ML) stability scores. A high score in the OA index indicates poor balance. The OA stability score is believed to be the best indicator of the overall ability of the patient to balance the platform
The invention belongs to cosmetic field, particularly relate to a kind of Gynura procumbens (Lour.) Merr. and namely imitate natural compound recipe facial film of polynary maintenance and preparation method thereof.It is characterized in that: Gynura procumbens (Lour.) Merr. facial film is made up of following percentage by weight raw material: Gynura procumbens (Lour.) Merr. extract 93-96%, Camellia oil 0.5-1.5%, wild Hibisci Mutabilis Mel 2.5-5%, Herba Rosmarini Officinalis 0.3-1%.With Gynura procumbens (Lour.) Merr. extract for the main plant essence liquid adjuvant adding a small amount of function.Facial film in the present invention can play moisturizing to human body skin, it is wrinkle resistant to brighten, anti-inflammation, lift are compacted, light speckle acne removing, and do not add any man-made additive, and preparation method is simple.
Over time, the number of patients on the lung transplant waiting list and the number of lung transplants performed have greatly increased. Unfortunately, the number of patients on the waiting list has outpaced the transplant rate, resulting in a significant number of deaths for patients on the waiting list.

Live lung donation has the potential to decrease wait time for lung transplants and the rate of death for those awaiting transplants. However, since live lung donation typically utilizes one lobe of lung from each of two donors, transplantation puts two donors at risk for adverse events. Although live lung donation began in the early 1990s, there is still a great lack of published and comprehensive, long-term studies, leaving the outcome of live lung donation unclear. This study will assess post-donation outcomes in live lung donors. Specifically, investigators will determine the effects of live lung donation on lung function, quality of life, morbidity, psychosocial status, satisfaction with live lung donation, and decision-making associated with live lung donation. Information obtained from this study will allow potential future live lung donors and the interested public to become better informed, and may also assist potential donors in their decision-making process regarding the procedure. Furthermore, positive study results could potentially reassure previous live organ donors about uncertainties concerning their future health.

There will be 369 participants recruited for this study based on live lung donations, which occurred from 1993 through 2006. Study coordinators will contact eligible participants inviting participants to the study and answering any questions. Participants will have the option to partially or completely refuse participation. Each consenting donor will complete a series of questionnaires via phone and mail. The questions address issues related to the donor's quality of life, morbidity, psychosocial status, satisfaction with live lung donation, and decision-making associated with live lung donation. The questionnaires will take about one hour to complete. The coordinator will offer assistance regarding questionnaire completion and return. At the end of the study, a final brief status update will be obtained via phone interview.

In addition to questionnaires, participants will also be asked to participate in spirometry testing. For consenting participants, spirometry testing will be scheduled at either the two study sites or an approved Pulmonary Function Laboratory. During the test, the participant will breathe in and out of a plastic tube while a machine measures the amount and flow of air the donor breathes in and out. If deemed appropriate, the participant will do this test again a few minutes after being given albuterol, a drug which aims to optimize lung function. Spirometry testing will last about an hour.